A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis

Completed · Phase 1 · Has a placebo group

Conditions studied: Osteoarthritis, Knee

In brief

This study will evaluate the safety and tolerability of KA34 when administered via intra-articular injection to subjects with osteoarthritis of the knee.

Key facts

Study ID

NCT03133676

Run by

Calibr, a division of Scripps Research

People needed

60

Starts

2018-05-02

Expected to finish

2020-04-28

Last updated by the study team

2022-12-27

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of localized osteoarthritis of the knee
• Males willing to use contraception and females who are no longer able to bear children

You may not qualify if…

• Body Mass Index (BMI) > 40
• Grade 0, 3 or 4 osteoarthritis on the Kellgren and Lawrence classification system
• Injury to the knee or other joint within the last 12 months
• Receipt of any investigational product or experimental therapeutic procedure within the last 12 weeks

Where it is running

• Diablo Clinical Research — Walnut Creek, California, United States
• Clinical Research of West Florida — Clearwater, Florida, United States
• Bioclinica Research — Orlando, Florida, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.